VTCN1 and breast carcinoma: Therefore, it seems that B7-H4 neutralizing antibodies vastly reduce tumor cell viability in vitro, and the protein confers resistance to doxorubicin by reducing the sensitivity of breast cancer cells to apoptosis, mediated via the PTEN/PI3K/Akt pathway [91].